Ionis Pharmaceuticals, Inc.
IONSHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeIonis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company carries a $12.78B market cap, placing it firmly in the large-cap category. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Market Cap
$12.78B
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
-124.34
EPS (TTM)
$-2.01
EPS (Fwd)
$-0.62
ROE
-67.6%
ROA
-7.0%
Cash
$1.98B
Total Debt
$2.61B
Free CF
-$807.8M
52W Change
130.8%
Annual Financials
Cash vs Debt
The company holds $1.98B in cash, though total debt stands at $2.61B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$807.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -67.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $587.4M (2022) to $943.7M (2025), reflecting a 61% increase over the period.
IONS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ionis Pharmaceuticals, Inc.'s trajectory.